An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
Shares of Denmark's Zealand Pharma rose 35% on Monday after results showed success in its liver disease treatment survodutide ...
Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.